Back
Arrowhead Pharmaceuticals Inc (ARWR)
BiotechnologyARWR · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$88.83
+2.37%Weekly undervalued picks
Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for research and education only. Not financial advice.
Key metrics
EPS
$-0.01
ROE
-42.4%
Gross margin
100.0%
Debt/Equity
2.31x
Revenue growth
-86.4%
Arrowhead Pharmaceuticals Inc — company intelligence
Earnings surprises
Q3 2026$-1.36 vs $-1.35 est-1.0%
Q2 2026$-0.93 vs $-1.21 est+23.2%
Q1 2026$0.22 vs $0.26 est-14.8%
Q4 2025$-0.18 vs $-0.25 est+26.7%
Analyst consensus · 20 analysts
19 Buy1 Hold0 Sell
Updated Aug 22, 2026
Recent SEC filings
4 — Insider transaction reportAug 20, 2026
4 — Insider transaction reportAug 20, 2026
8-K — Material event reportAug 4, 2026
Latest news
Arrowhead Pharma’s REDEMPLO Authorized In EU; Now Prescribable And Reimbursable In Germany For Familial Chylomicronaemia Syndrome — Benzinga · 1w ago
‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit — Yahoo · 2w ago
HC Wainwright & Co. Maintains Buy on Arrowhead Pharma, Raises Price Target to $120 — Benzinga · 2w ago
ARWR: Acquires PRV for sNDA Submission for Plozasiran in sHTG — Yahoo · 2w ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
Weekly undervalued picks
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.